Strong Q1 operating profit hides weaker revenues at new-look Novartis
This article was originally published in Scrip
Executive Summary
Swiss major Novartis missed its consensus revenues estimates but nonetheless posted a very healthy operating profit in the first quarter thanks largely to higher margins in its pharma and Sandoz divisions.